Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 11 01:51PM ET
16.24
Dollar change
+0.94
Percentage change
6.15
%
Index- P/E- EPS (ttm)-4.96 Insider Own12.45% Shs Outstand48.74M Perf Week158.20%
Market Cap791.61M Forward P/E- EPS next Y-3.32 Insider Trans-0.57% Shs Float42.67M Perf Month112.02%
Income-239.50M PEG- EPS next Q-0.67 Inst Own75.05% Short Float7.62% Perf Quarter193.15%
Sales28.59M P/S27.69 EPS this Y36.58% Inst Trans19.19% Short Ratio1.87 Perf Half Y207.59%
Book/sh1.15 P/B14.18 EPS next Y19.07% ROA-31.57% Short Interest3.25M Perf Year127.46%
Cash/sh8.93 P/C1.82 EPS next 5Y- ROE-147.56% 52W Range3.73 - 17.39 Perf YTD139.89%
Dividend Est.- P/FCF- EPS past 5Y-22.59% ROI-43.88% 52W High-6.61% Beta0.75
Dividend TTM- Quick Ratio6.51 Sales past 5Y302.35% Gross Margin-36.48% 52W Low335.40% ATR (14)1.34
Dividend Ex-Date- Current Ratio6.51 EPS Y/Y TTM-3.34% Oper. Margin-710.49% RSI (14)87.13 Volatility14.39% 9.51%
Employees480 Debt/Eq8.85 Sales Y/Y TTM-74.45% Profit Margin-837.80% Recom1.46 Target Price29.00
Option/ShortYes / Yes LT Debt/Eq8.78 EPS Q/Q51.42% Payout- Rel Volume3.56 Prev Close15.30
Sales Surprise-66.65% EPS Surprise8.33% Sales Q/Q62.54% EarningsNov 05 BMO Avg Volume1.74M Price16.24
SMA20122.75% SMA50145.31% SMA200176.32% Trades Volume4,234,174 Change6.15%
Date Action Analyst Rating Change Price Target Change
Dec-10-24Upgrade Raymond James Outperform → Strong Buy
Oct-10-24Resumed Raymond James Outperform $20
Feb-29-24Downgrade Goldman Buy → Neutral $8
Dec-19-23Downgrade Mizuho Buy → Neutral $52 → $10
Mar-17-22Upgrade UBS Neutral → Buy $40
Jun-15-21Initiated BTIG Research Buy $46
May-21-21Initiated UBS Neutral $40
Apr-26-21Resumed Credit Suisse Outperform $78
Apr-01-21Upgrade Mizuho Neutral → Buy $52
Jan-07-21Upgrade Guggenheim Neutral → Buy $62
Dec-10-24 05:11PM
09:34AM
07:07AM
07:05AM
Nov-29-24 09:55AM
12:00PM Loading…
Nov-28-24 12:00PM
Nov-21-24 07:05AM
Nov-08-24 09:55AM
Nov-05-24 08:30AM
07:26AM
07:05AM
Oct-29-24 10:01AM
Oct-18-24 03:03PM
Oct-15-24 07:05AM
07:05AM
07:05AM Loading…
Sep-23-24 07:05AM
Aug-15-24 07:05AM
Aug-01-24 12:51PM
08:25AM
07:22AM
07:05AM
Jul-26-24 09:55AM
Jul-23-24 07:05AM
Jul-12-24 07:12AM
Jul-10-24 09:55AM
09:01AM
05:49AM
Jul-09-24 10:46AM
10:27AM
09:35AM
08:05AM Loading…
08:05AM
07:05AM
Jul-01-24 07:05AM
07:05AM
06:30AM
Jun-03-24 07:05AM
May-07-24 01:53PM
07:24AM
07:05AM
Mar-13-24 07:07AM
Feb-29-24 09:06AM
Feb-28-24 08:35AM
08:20AM
07:05AM
Feb-27-24 03:30AM
Dec-19-23 07:15AM
07:05AM
Dec-11-23 07:30PM
Dec-10-23 11:59AM
Dec-08-23 07:05AM
04:08AM
Nov-29-23 07:05AM
Nov-14-23 10:31PM
Nov-08-23 09:55AM
Nov-07-23 08:25AM
08:12AM
07:21AM
07:05AM
Oct-30-23 09:32AM
Oct-27-23 10:00AM
Oct-26-23 02:14PM
10:02AM
Oct-25-23 10:02AM
Oct-24-23 07:05AM
Oct-12-23 08:24AM
Oct-06-23 11:31AM
Oct-05-23 01:49PM
08:15AM
07:19AM
07:05AM
Oct-02-23 07:05AM
Sep-05-23 01:10PM
07:05AM
Sep-01-23 06:51PM
Aug-31-23 10:12PM
Aug-26-23 03:51PM
Aug-06-23 08:05AM
Aug-01-23 09:05AM
07:54AM
07:05AM
Jul-27-23 08:35PM
Jun-28-23 09:20AM
06:02AM
Jun-26-23 07:11AM
Jun-22-23 03:03PM
10:17AM
Jun-21-23 08:00PM
04:08PM
11:46AM
07:05AM
Jun-20-23 07:05AM
07:00AM
Jun-16-23 07:05AM
May-15-23 07:53AM
07:05AM
May-14-23 08:16AM
May-09-23 08:25AM
07:21AM
07:05AM
May-02-23 04:40PM
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kapusta Matthew CCEO, Managing DirectorDec 09 '24Sale7.633,41826,079597,915Dec 10 05:03 PM
KLEMT CHRISTIANChief Financial OfficerDec 09 '24Sale7.551,79613,560166,713Dec 10 04:54 PM
Matthew KapustaCEODec 10 '24Proposed Sale15.03100,0001,503,491Dec 10 04:33 PM
Abi-Saab WalidChief Medical OfficerJun 26 '24Sale4.361,4476,309115,253Jun 28 04:21 PM
CALOZ PIERREChief Operating OfficerJun 17 '24Sale4.812,93614,122115,707Jun 20 08:53 AM
KLEMT CHRISTIANChief Financial OfficerJun 17 '24Sale4.801,6117,733164,837Jun 20 08:49 AM
POST LEONARD EDirectorJun 13 '24Sale5.142,22211,42115,999Jun 18 06:11 PM
Potts JeannetteChief Legal OfficerJun 13 '24Sale4.984,78123,80991,819Jun 17 07:46 PM
Springhorn Jeremy P.DirectorJun 13 '24Sale5.122,23111,42323,756Jun 17 07:40 PM
Meek David D.DirectorJun 13 '24Sale5.122,22911,41220,252Jun 17 07:35 PM
Balachandran MadhavanDirectorJun 13 '24Sale5.122,23111,42323,759Jun 17 07:30 PM
Soteropoulos PaulaDirectorJun 13 '24Sale5.142,22011,41120,203Jun 17 07:24 PM
Gut RobertDirectorJun 13 '24Sale5.123,50417,94044,165Jun 17 07:19 PM
Kaye JackDirectorJun 13 '24Sale5.162,21811,4456,501Jun 17 07:14 PM
Jacques Rachelle SuzanneDirectorJun 13 '24Sale5.142,22111,41614,408Jun 17 06:42 PM
CALOZ PIERREChief Operating OfficerFeb 26 '24Sale6.479,45561,17485,643Feb 28 04:33 PM
KLEMT CHRISTIANChief Financial OfficerFeb 26 '24Sale6.3815,906101,480116,948Feb 28 04:21 PM
Kapusta Matthew CCEO, Managing DirectorFeb 26 '24Sale6.3527,904177,190440,839Feb 28 04:17 PM